THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES

Header Logo

Connection

James George to ADAMTS13 Protein

This is a "connection" page, showing publications James George has written about ADAMTS13 Protein.
Connection Strength

7.022
  1. Hereditary Thrombotic Thrombocytopenic Purpura. N Engl J Med. 2019 10 24; 381(17):1653-1662.
    View in: PubMed
    Score: 0.651
  2. Diagnosis of thrombotic thrombocytopenic purpura among patients with ADAMTS13 Activity 10%-20. Am J Hematol. 2017 Nov; 92(11):E644-E646.
    View in: PubMed
    Score: 0.562
  3. Clinical importance of ADAMTS13 activity during remission in patients with acquired thrombotic thrombocytopenic purpura. Blood. 2016 10 27; 128(17):2175-2178.
    View in: PubMed
    Score: 0.525
  4. Recombinant ADAMTS13: an effective rescue therapy for acute cTTP during pregnancy. Blood Adv. 2024 Jul 23; 8(14):3718-3720.
    View in: PubMed
    Score: 0.226
  5. Prevalence of neuropsychiatric symptoms and stroke in patients with hereditary thrombotic thrombocytopenic purpura. Blood. 2022 08 18; 140(7):785-789.
    View in: PubMed
    Score: 0.198
  6. Recognizing and managing hereditary and acquired thrombotic thrombocytopenic purpura in infants and children. Pediatr Blood Cancer. 2021 05; 68(5):e28949.
    View in: PubMed
    Score: 0.179
  7. Hereditary Thrombotic Thrombocytopenic Purpura. Reply. N Engl J Med. 2020 01 23; 382(4):394-395.
    View in: PubMed
    Score: 0.166
  8. Congenital TTP: toward a turning point. Blood. 2019 04 11; 133(15):1615-1617.
    View in: PubMed
    Score: 0.157
  9. The International Hereditary Thrombotic Thrombocytopenic Purpura Registry: key findings at enrollment until 2017. Haematologica. 2019 10; 104(10):2107-2115.
    View in: PubMed
    Score: 0.155
  10. Maintenance rituximab for relapsing thrombotic thrombocytopenic purpura: a case report. Transfusion. 2019 03; 59(3):921-926.
    View in: PubMed
    Score: 0.153
  11. The remarkable diversity of thrombotic thrombocytopenic purpura: a perspective. Blood Adv. 2018 06 26; 2(12):1510-1516.
    View in: PubMed
    Score: 0.148
  12. Rituximab for thrombotic thrombocytopenic purpura: lessons from the STAR trial. Transfusion. 2017 10; 57(10):2532-2538.
    View in: PubMed
    Score: 0.139
  13. Congenital thrombotic thrombocytopenic purpura related to a novel mutation in ADAMTS13 gene and management during pregnancy. Am J Hematol. 2016 06; 91(6):644-6.
    View in: PubMed
    Score: 0.129
  14. Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura. Blood. 2016 06 16; 127(24):3092-4.
    View in: PubMed
    Score: 0.127
  15. Depression and cognitive impairment following recovery from thrombotic thrombocytopenic purpura. Am J Hematol. 2015 Aug; 90(8):709-14.
    View in: PubMed
    Score: 0.120
  16. The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura. Blood. 2015 Mar 05; 125(10):1526-31.
    View in: PubMed
    Score: 0.117
  17. Measuring ADAMTS13 activity in patients with suspected thrombotic thrombocytopenic purpura: when, how, and why? Transfusion. 2015 Jan; 55(1):11-3.
    View in: PubMed
    Score: 0.117
  18. Increased urinary albumin excretion following recovery from thrombotic thrombocytopenic purpura due to acquired ADAMTS13 deficiency. Am J Kidney Dis. 2014 Aug; 64(2):317-8.
    View in: PubMed
    Score: 0.111
  19. Pregnancy outcomes following recovery from acquired thrombotic thrombocytopenic purpura. Blood. 2014 Mar 13; 123(11):1674-80.
    View in: PubMed
    Score: 0.109
  20. Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura. Blood. 2013 Sep 19; 122(12):2023-9; quiz 2142.
    View in: PubMed
    Score: 0.105
  21. Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features. Pediatr Blood Cancer. 2013 Oct; 60(10):1676-82.
    View in: PubMed
    Score: 0.104
  22. Ten patient stories illustrating the extraordinarily diverse clinical features of patients with thrombotic thrombocytopenic purpura and severe ADAMTS13 deficiency. J Clin Apher. 2012; 27(6):302-11.
    View in: PubMed
    Score: 0.099
  23. Corticosteroids and rituximab as adjunctive treatments for thrombotic thrombocytopenic purpura. Am J Hematol. 2012 May; 87 Suppl 1:S88-91.
    View in: PubMed
    Score: 0.096
  24. Diagnostic and therapeutic challenges in the thrombotic thrombocytopenic purpura and hemolytic uremic syndromes. Hematology Am Soc Hematol Educ Program. 2012; 2012:604-9.
    View in: PubMed
    Score: 0.095
  25. Systemic infections mimicking thrombotic thrombocytopenic purpura. Am J Hematol. 2011 Sep; 86(9):743-51.
    View in: PubMed
    Score: 0.093
  26. Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolytic-uremic syndromes. Am J Hematol. 2010 Nov; 85(11):844-7.
    View in: PubMed
    Score: 0.087
  27. How I treat patients with thrombotic thrombocytopenic purpura: 2010. Blood. 2010 Nov 18; 116(20):4060-9.
    View in: PubMed
    Score: 0.086
  28. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood. 2010 Feb 25; 115(8):1500-11; quiz 1662.
    View in: PubMed
    Score: 0.082
  29. Frequency and significance of HIV infection among patients diagnosed with thrombotic thrombocytopenic purpura. Clin Infect Dis. 2009 Apr 15; 48(8):1129-37.
    View in: PubMed
    Score: 0.078
  30. Cognitive deficits after recovery from thrombotic thrombocytopenic purpura. Transfusion. 2009 Jun; 49(6):1092-101.
    View in: PubMed
    Score: 0.078
  31. Clinical outcomes after platelet transfusions in patients with thrombotic thrombocytopenic purpura. Transfusion. 2009 May; 49(5):873-87.
    View in: PubMed
    Score: 0.077
  32. The thrombotic thrombocytopenic purpura and hemolytic uremic syndromes: evaluation, management, and long-term outcomes experience of the Oklahoma TTP-HUS Registry, 1989-2007. Kidney Int Suppl. 2009 Feb; (112):S52-4.
    View in: PubMed
    Score: 0.077
  33. The thrombotic thrombocytopenic purpura and hemolytic uremic syndromes: overview of pathogenesis (Experience of The Oklahoma TTP-HUS Registry, 1989-2007). Kidney Int Suppl. 2009 Feb; (112):S8-S10.
    View in: PubMed
    Score: 0.077
  34. ADAMTS13: what it does, how it works, and why it's important. Transfusion. 2009 Feb; 49(2):196-8.
    View in: PubMed
    Score: 0.077
  35. Pregnancy-induced thrombocytopenia and TTP, and the risk of fetal death, in Upshaw-Schulman syndrome: a series of 15 pregnancies in 9 genotyped patients. Br J Haematol. 2009 Mar; 144(5):742-54.
    View in: PubMed
    Score: 0.076
  36. Clinical insights from observations on ADAMTS13 deficiency in liver cirrhosis. Thromb Haemost. 2008 Jun; 99(6):987-8.
    View in: PubMed
    Score: 0.074
  37. Congenital thrombotic thrombocytopenic purpura: Lessons for recognition and management of rare syndromes. Pediatr Blood Cancer. 2008 May; 50(5):947-8.
    View in: PubMed
    Score: 0.073
  38. Sporadic bloody diarrhoea-associated thrombotic thrombocytopenic purpura-haemolytic uraemic syndrome: an adult and paediatric comparison. Br J Haematol. 2008 May; 141(5):696-707.
    View in: PubMed
    Score: 0.073
  39. Acquired thrombotic thrombocytopenic purpura: ADAMTS13 activity, anti-ADAMTS13 autoantibodies and risk of recurrent disease. Haematologica. 2008 Feb; 93(2):172-7.
    View in: PubMed
    Score: 0.072
  40. Lessons learned from the Oklahoma thrombotic thrombocytopenic purpura-hemolytic uremic syndrome registry. J Clin Apher. 2008; 23(4):129-37.
    View in: PubMed
    Score: 0.072
  41. Overlapping features of thrombotic thrombocytopenic purpura and systemic lupus erythematosus. South Med J. 2007 May; 100(5):512-4.
    View in: PubMed
    Score: 0.068
  42. Evaluation and management of patients with thrombotic thrombocytopenic purpura. J Intensive Care Med. 2007 Mar-Apr; 22(2):82-91.
    View in: PubMed
    Score: 0.068
  43. Clinical practice. Thrombotic thrombocytopenic purpura. N Engl J Med. 2006 May 04; 354(18):1927-35.
    View in: PubMed
    Score: 0.064
  44. The role of ADAMTS13 in the pathogenesis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clin Adv Hematol Oncol. 2005 Aug; 3(8):627-32.
    View in: PubMed
    Score: 0.061
  45. The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. J Thromb Haemost. 2005 Jul; 3(7):1432-6.
    View in: PubMed
    Score: 0.060
  46. ADAMTS13, thrombotic thrombocytopenic purpura, and hemolytic uremic syndrome. Curr Hematol Rep. 2005 May; 4(3):167-9.
    View in: PubMed
    Score: 0.060
  47. Thrombotic thrombocytopenic purpura: advances in pathophysiology, diagnosis, and treatment--introduction. Semin Hematol. 2004 Jan; 41(1):1-3.
    View in: PubMed
    Score: 0.054
  48. The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) Registry: a community perspective of patients with clinically diagnosed TTP-HUS. Semin Hematol. 2004 Jan; 41(1):60-7.
    View in: PubMed
    Score: 0.054
  49. Thrombotic thrombocytopenic purpura: a syndrome that keeps evolving. J Clin Apher. 2004; 19(2):63-5.
    View in: PubMed
    Score: 0.054
  50. Recent advances in thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program. 2004; 407-23.
    View in: PubMed
    Score: 0.054
  51. The association of pregnancy with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Curr Opin Hematol. 2003 Sep; 10(5):339-44.
    View in: PubMed
    Score: 0.053
  52. Thrombotic thrombocytopenic purpura: from the bench to the bedside, but not yet to the community. Ann Intern Med. 2003 Jan 21; 138(2):152-3.
    View in: PubMed
    Score: 0.051
  53. Endothelial VWF is critical for the pathogenesis of vaso-occlusive episode in a mouse model of sickle cell disease. Proc Natl Acad Sci U S A. 2022 08 23; 119(34):e2207592119.
    View in: PubMed
    Score: 0.049
  54. Aspirin prophylaxis for hereditary and acquired thrombotic thrombocytopenic purpura? Am J Hematol. 2022 08; 97(8):E304-E306.
    View in: PubMed
    Score: 0.049
  55. Platelets: thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program. 2002; 315-34.
    View in: PubMed
    Score: 0.047
  56. Redefining outcomes in immune TTP: an international working group consensus report. Blood. 2021 04 08; 137(14):1855-1861.
    View in: PubMed
    Score: 0.045
  57. Shared decision making, thrombotic thrombocytopenic purpura, and caplacizumab. Am J Hematol. 2020 04; 95(4):E76-E77.
    View in: PubMed
    Score: 0.041
  58. Successful kidney transplantation in a patient with congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome). Transfusion. 2017 12; 57(12):3058-3062.
    View in: PubMed
    Score: 0.035
  59. Ribosomal and immune transcripts associate with relapse in acquired ADAMTS13-deficient thrombotic thrombocytopenic purpura. PLoS One. 2015; 10(2):e0117614.
    View in: PubMed
    Score: 0.029
  60. Pulmonary involvement in patients with thrombotic thrombocytopenic purpura. Eur J Haematol. 2014 Feb; 92(2):156-63.
    View in: PubMed
    Score: 0.027
  61. Decreasing frequency of plasma exchange complications in patients treated for thrombotic thrombocytopenic purpura-hemolytic uremic syndrome, 1996 to 2011. Transfusion. 2012 Dec; 52(12):2525-32; quiz 2524.
    View in: PubMed
    Score: 0.024
  62. Evidence for a role of anti-ADAMTS13 autoantibodies despite normal ADAMTS13 activity in recurrent thrombotic thrombocytopenic purpura. Haematologica. 2012 Feb; 97(2):297-303.
    View in: PubMed
    Score: 0.023
  63. Blood group O and black race are independent risk factors for thrombotic thrombocytopenic purpura associated with severe ADAMTS13 deficiency. Transfusion. 2011 Oct; 51(10):2237-43.
    View in: PubMed
    Score: 0.022
  64. Demographic and ADAMTS13 biomarker data as predictors of early recurrences of idiopathic thrombotic thrombocytopenic purpura. Eur J Haematol. 2009 Dec 01; 83(6):559-64.
    View in: PubMed
    Score: 0.020
  65. Effect of prophylactic cyclosporine therapy on ADAMTS13 biomarkers in patients with idiopathic thrombotic thrombocytopenic purpura. Am J Hematol. 2008 Dec; 83(12):911-5.
    View in: PubMed
    Score: 0.019
  66. Cyclosporin and plasma exchange in thrombotic thrombocytopenic purpura: long-term follow-up with serial analysis of ADAMTS13 activity. Br J Haematol. 2007 Nov; 139(3):486-93.
    View in: PubMed
    Score: 0.018
  67. An evaluation of cyclosporin and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic thrombocytopenic purpura. Br J Haematol. 2007 Jan; 136(1):146-9.
    View in: PubMed
    Score: 0.017
  68. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood. 2003 Jul 01; 102(1):60-8.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES